3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
4
Sarcoma
2
Conditions
Neoplasms
2
Gliosarcoma
2
Glioblastoma
2
Brain Neoplasms
2
Recurrence
1
Interventions
Doxorubicin
44
Imatinib Mesylate
33
pembrolizumab
23
Cyclophosphamide
23
Sunitinib
22
Gemcitabine
22
Temozolomide
17
Irinotecan
14
Bevacizumab
14
Docetaxel
13
nilotinib
12
Trabectedin
12
ripretinib
11
pazopanib
11
olaratumab
10
fludarabine
10
eribulin
10
regorafenib
9
avapritinib
9
Fluorouracil
9
Carboplatin
9
Paclitaxel
8
Nivolumab
8
Ifosfamide
8
Ibandronic Acid
8
spartalizumab
7
anlotinib
7
Vincristine
7
Radiation
7
Ipilimumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
rindopepimut
×
Sarcoma
×
Clear all
NCT01498328
2020-02-17
ReACT
Celldex Therapeutics
Phase 2
Completed
127 enrolled
NCT01480479
2018-01-16
ACT IV
Celldex Therapeutics
Phase 3
Completed
745 enrolled